Adaptive Biotechnologies Corp
For the period ended Jun 30, 2024. Filed Aug 1, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 1, 2024
ADPT$30.26+8.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity
(in thousands, except share amounts)
| Common Stock · Additional · Accumulated Other · Accumulated · Noncontrolling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Paid-In Capital | Comprehensive Loss | Deficit | Interest | Shareholders’ Equity | |
| Balance at March 31, 2023 | 144,279,969 | $14 | $1,402,692 | $(1,905) | $(976,781) | $(68) | $423,952 |
| Issuance of common stock for cash upon exercise of stock options | 201,647 | — | 1,469 | — | — | — | 1,469 |
| Vesting of restricted stock units | 163,502 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 17,345 | — | — | — | 17,345 |
| Other comprehensive income | — | — | — | 1,012 | — | — | 1,012 |
| Net loss | — | — | — | — | (47,810) | (1) | (47,811) |
| Balance at June 30, 2023 | 144,645,118 | $14 | $1,421,506 | $(893) | $(1,024,591) | $(69) | $395,967 |
| Balance at March 31, 2024 | 147,368,324 | $14 | $1,466,844 | $(106) | $(1,191,839) | $(147) | $274,766 |
| Issuance of common stock for cash upon exercise of stock options | 15,000 | — | 30 | — | — | — | 30 |
| Vesting of restricted stock units, net | 78,877 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 12,958 | — | — | — | 12,958 |
| Other comprehensive loss | — | — | — | (76) | — | — | (76) |
| Net loss | — | — | — | — | (46,222) | (26) | (46,248) |
| Balance at June 30, 2024 | 147,462,201 | $14 | $1,479,832 | $(182) | $(1,238,061) | $(173) | $241,430 |
Condensed Consolidated Statements of Shareholders’ Equity (Continued)
(in thousands, except share amounts)
| Common Stock · Additional · Accumulated Other · Accumulated · Noncontrolling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Paid-In Capital | Comprehensive (Loss) Gain | Deficit | Interest | Shareholders’ Equity | |
| Balance at December 31, 2022 | 143,105,002 | $14 | $1,387,349 | $(4,116) | $(919,082) | $(67) | $464,098 |
| Issuance of common stock for cash upon exercise of stock options | 347,405 | — | 2,141 | — | — | — | 2,141 |
| Vesting of restricted stock units | 1,192,711 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 32,016 | — | — | — | 32,016 |
| Other comprehensive income | — | — | — | 3,223 | — | — | 3,223 |
| Net loss | — | — | — | — | (105,509) | (2) | (105,511) |
| Balance at June 30, 2023 | 144,645,118 | $14 | $1,421,506 | $(893) | $(1,024,591) | $(69) | $395,967 |
| Balance at December 31, 2023 | 145,082,271 | $14 | $1,452,502 | $215 | $(1,144,332) | $(121) | $308,278 |
| Issuance of common stock for cash upon exercise of stock options | 45,900 | — | 74 | — | — | — | 74 |
| Vesting of restricted stock units, net | 2,334,030 | — | — | — | — | — | — |
| Share-based compensation expense | — | — | 27,256 | — | — | — | 27,256 |
| Other comprehensive loss | — | — | — | (397) | — | — | (397) |
| Net loss | — | — | — | — | (93,729) | (52) | (93,781) |
| Balance at June 30, 2024 | 147,462,201 | $14 | $1,479,832 | $(182) | $(1,238,061) | $(173) | $241,430 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.